筛查发现的2型糖尿病强化多因素治疗的长期效果:ADDITION-Europe集群随机试验10年随访
ADDITION-Europe研究在四个中心对筛查发现的2型糖尿病患者进行集群随机分组,比较常规护理与强化多因素治疗。5年干预结束后不再维持治疗差异,post-hoc分析10年随访显示两组体重、HbA1c、血压和胆固醇均有持续下降,但组间差异在10年时减弱;
要点
- 筛查发现的2型糖尿病患者10年内可实现血糖及心血管危险因素的持续改善
- 强化治疗组与常规护理组在10年时主要心血管复合终点无显著差异
- 干预结束后治疗差异未能维持,组间危险因素差异随时间减弱
核心结论
- 在初级保健中管理的筛查发现的2型糖尿病患者,10年内可实现血糖及相关心血管危险因素的持续下降。
- 诊断后5年内的处方治疗和心血管危险因素差异在10年时未能维持,心血管事件和死亡率的差异仍无统计学意义。
研究设计与样本
- 多中心、国际、集群随机试验的post-hoc 10年随访分析,纳入丹麦、剑桥(英国)、莱斯特(英国)和荷兰四个中心的全科诊所。
- 343个全科诊所随机分配至常规糖尿病护理组(n=176)或强化多因素治疗组(n=167),其中317个诊所纳入符合条件的患者。
- 3233例筛查发现的2型糖尿病患者中3057例同意参与(常规护理组1379例,强化治疗组1678例),10年随访时14例失访、12例退出,最终3031例进入分析。
- 主要终点为首次心血管事件复合终点(心血管死亡、心血管疾病包括非致死性心肌梗死和非致死性卒中、血运重建、非创伤性截肢),截至2014年12月31日,按意向性治疗原则分析。
主要发现
- 10年随访期间两组体重、HbA1c、血压和胆固醇均持续下降,但1年和5年时观察到的组间差异在10年随访时减弱。
- 10年内共443例发生首次心血管事件,465例死亡。
临床怎么用
- 在初级保健中对筛查发现的2型糖尿病患者实施强化多因素治疗可望在长期内持续改善血糖和心血管危险因素。
- 5年强化干预结束后若不再维持治疗差异,心血管获益可能有限,提示需要长期持续管理。
局限性
- 本研究为post-hoc分析,5年干预结束后未尝试维持组间治疗差异,可能影响长期组间比较的解释。
- 随访期间14例失访、12例退出,可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The multicentre, international ADDITION-Europe study investigated the effect of promoting intensive treatment of multiple risk factors among people with screen-detected type 2 diabetes over 5 years. Here we report the results of a post-hoc 10-year follow-up analysis of ADDITION-Europe to establish whether differences in treatment and cardiovascular risk factors have been maintained and to assess effects on cardiovascular outcomes. METHODS: As previously described, general practices from four centres (Denmark, Cambridge [UK], Leicester [UK], and the Netherlands) were randomly assigned by computer-generated list to provide screening followed by routine care of diabetes, or screening followed by intensive multifactorial treatment. Population-based stepwise screening programmes among people aged 40-69 years (50-69 years in the Netherlands), between April, 2001, and December, 2006, identified patients with type 2 diabetes. Allocation was concealed from patients. Following the 5-year follow-up, no attempts were made to maintain differences in treatment between study groups. In this report, we did a post-hoc analysis of cardiovascular and renal outcomes over 10 years following randomisation, including a 5 years post-intervention follow-up. As in the original trial, the primary endpoint was a composite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014. Analyses were based on the intention-to-treat principle. ADDITION-Europe is registered with ClinicalTrials.gov, NCT00237549. FINDINGS: 343 general practices were randomly assigned to routine diabetes care (n=176) or intensive multifactorial treatment (n=167). 317 of these general practices (157 in the routine care group, 161 in the intensive treatment group) included eligible patients between April, 2001, and December, 2006. Of the 3233 individuals with screen-detected diabetes, 3057 agreed to participate (1379 in the routine care group, 1678 in the intensive treatment group), but at the 10-year follow-up 14 were lost to follow-up and 12 withdrew, leaving 3031 to enter 10-year follow-up analysis. Mean duration of follow-up was 9·61 years (SD 2·99). Sustained reductions over 10 years following diagnosis were apparent for bodyweight, HbA1c, blood pressure, and cholesterol in both study groups, but between-group differences identified at 1 and 5 years were attenuated at the 10-year follow-up. By 10 years, 443 participants had a first cardiovascular event and 465 died. There was no significant difference between groups in the incidence of the primary composite outcome (16·1 per 1000 person-years in the routine care group vs 14·3 per 1000 person-years in the intensive treatment group; hazard ratio [HR] 0·87, 95% CI 0·73-1·04; p=0·14) or all-cause mortality (15·6 vs 14·3 per 1000 person-years; HR 0·90, 0·76-1·07). INTERPRETATION: Sustained reductions in glycaemia and related cardiovascular risk factors over 10 years among people with screen-detected diabetes managed in primary care are achievable. The differences in prescribed treatment and cardiovascular risk factors in the 5 years following diagnosis were not maintained at 10 years, and the difference in cardiovascular events and mortality remained non-significant. FUNDING: National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for General Practice, Novo Nordisk, Novo Nordisk Foundation, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, Danish Medical Research Council, Aarhus University Research Foundation, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Wellcome Trust, UK Medical Research Council, UK National Institute for Health Research, UK National Health Service, Merck, Julius Center for Health Sciences and Primary Care, UK Department of Health, and Nuts-OHRA.
引用
- Griffin SJ, Rutten GEHM, Khunti K, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol. 2019. PMID: 31748169. doi:10.1016/S2213-8587(19)30349-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。